The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant versus adjuvant chemotherapy with taxanes and anthracycline-based regimen: Which leads to better outcome in patients with different subtype breast cancer?
Houpu Yang
Disclosure not yet available
Shu Wang
Disclosure not yet available
Lixin Zhou
Disclosure not yet available
Jiajia Guo
Disclosure not yet available
Yingming Cao
Disclosure not yet available
Bo Zhou
Disclosure not yet available
Lin Cheng
Disclosure not yet available
Fei Xie
Disclosure not yet available
Hongjun Liu
Disclosure not yet available
Fuzhong Tong
Disclosure not yet available
Miao Liu
Disclosure not yet available
Peng Liu
Disclosure not yet available
Siyuan Wang
Disclosure not yet available
Deqi Yang
Disclosure not yet available
Jiaqing Zhang
Disclosure not yet available